Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on HRS-5965 PK in healthy subjects
NCT07035665Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-5965 in IgA nephropathy (IgAN) and paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoints: Peak Concentration and Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Timepoint. Started Jun 2025; status: completed.
02
Drugs
HRS-5965
03
Conditions
IgA nephropathy (IgAN)paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07035665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035665.